[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.196.37. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
October 18, 2000

Dopamine Agonists in Early Therapy for Parkinson DiseasePromise and Problems

Author Affiliations

Author Affiliation: Parkinson's Institute, Sunnyvale, Calif.

JAMA. 2000;284(15):1971-1973. doi:10.1001/jama.284.15.1971

The successful use of levodopa, the immediate precursor of dopamine, to reverse motor deficits in Parkinson disease (PD) revolutionized treatment.1 But for most patients with PD, the benefits of levodopa therapy have been tempered by adverse effects such as involuntary movements or hallucinations. These adverse effects occur in as many as 90% of patients receiving long-term treatment, although whether they are actually caused by levodopa treatment, or simply reflect progression of the underlying disease, is unknown.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×